$288 Million

Annexon, Inc.

Initial Public Offering

Bookrunner, July 2020

Annexon, Inc.

Annexon Biosciences, Inc. is a clinical-stage biopharmaceutical company targeting C1q, the initiating molecule of the classical complement pathway, to develop transformative therapies for autoimmune and neurodegenerative disorders of the body, eye and brain. The Company’s lead product candidate is ANX005, a monoclonal antibody that blocks the activation of the classical complement cascade at its initiation point by binding and blocking the function of C1q. ANX005 is initially being developed for the treatment of Guillain-Barré Syndrome, or GBS, a rare, acute, antibody-mediated autoimmune disease impacting the peripheral nervous system. The Company’s second product candidate, ANX007, is an antigen-binding fragment, or Fab, that is designed as an intravitreal agent for the treatment of ophthalmic neurodegenerative disorders.